Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

Integrated Somatic Mutation and DNA Methylation Analysis Reveal Genomic and Epigenomic Co-Evolution In Follicular Lymphomas

Markus Loeffler, Prof MD PhD, Markus Kreuz, Andrea Haake, Dirk Hasenclever, PhD, Heiko Trautmann, PhD, Christian Arnold, Karsten Winter, Wolfram Klapper, René Scholtysik, Maciej Rosolowski, PhD, Steve Hoffmann, Ole Ammerpohl, Monika Szczepanowski, Dietrich Herrmann, Ralf Kueppers, Prof, Christiane Pott, M.D. Ph.D., Reiner Siebert, MD

Blood (2013) 122 (21): 502.

https://doi.org/10.1182/blood.V122.21.502.502

Published: 2013

Journal Articles

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

Wolfram Klapper, Markus Kreuz, Christian W. Kohler, Birgit Burkhardt, Monika Szczepanowski, Itziar Salaverria, Michael Hummel, Markus Loeffler, Shoji Pellissery, Wilhelm Woessmann, Carsten Schwänen, Lorenz Trümper, Swen Wessendorf, Rainer Spang, Dirk Hasenclever, Reiner Siebert, for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe

Blood (2012) 119 (8): 1882–1887.

https://doi.org/10.1182/blood-2011-10-388470

Published: 2012

Includes: Supplemental data

Journal Articles

Prognostic Impact of Early and Late 18 fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Prior to Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed or Refractory Hodgkin Lymphoma

Blood (2011) 118 (21): 3108.

https://doi.org/10.1182/blood.V118.21.3108.3108

Published: 2011

Journal Articles

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults

Blood (2011) 118 (1): 139–147.

https://doi.org/10.1182/blood-2011-01-330795

Published: 2011

Includes: Supplemental data

Journal Articles

New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling

Blood (2009) 113 (11): 2488–2497.

https://doi.org/10.1182/blood-2008-04-152900

Published: 2009

Includes: Supplemental data

Journal Articles

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

Blood (2008) 112 (11): 2966.

https://doi.org/10.1182/blood.V112.11.2966.2966

Published: 2008

Journal Articles

Surgical Resection Alone in Children with Limited Stage Lymphocyte Predominant Hodgkin’s Lymphoma - The Experience of the EuroNet-PHL Group.

Christine Mauz-Koerholz, MD, PhD, Dirk Hasenclever, PhD, Stephanie Gorde-Grosjean, MD, Wolfgang Dörffel, MD, Günther Schellong, MD, PhD, Ananth Shankar, MD, Georgina Hall, MD, William H. Wallace, MD, Dieter Korholz, MD, PhD, Judith Landman-Parker, MD, PhD

Blood (2006) 108 (11): 2470.

https://doi.org/10.1182/blood.V108.11.2470.2470

Published: 2006

Journal Articles

Treatment of Children & Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] - on Behalf of the EuroNet-PHL Group.

Ananth G. Shankar, Stephen Daw, Georgina Hall, Stephanie Gorde-Grosjean, Christine Mauz Koerholz, Dieter Korholz, William H. Wallace, Dirk Hasenclever, Judith Landman-Parker

Blood (2006) 108 (11): 2471.

https://doi.org/10.1182/blood.V108.11.2471.2471

Published: 2006

Journal Articles

Response Adapted Therapy: Using FDG-PET after Chemotherapy in Order To Restrict Indication for Radiotherapy in Children and Adolescents with Early Stages of Hodgkin’s Lymphoma (HL).

Christine G. Mauz-Koerholz, MD, PhD, Regine Kluge, MD, PhD, Ina Sorge, MD, Barbara Merziger, Antje Krausse, MD, Dirk Hasenclever, PhD, Friedrich H. Kamprad, MD, PhD, H. Amthauer, MD, PhD, Christiane Franzius, MD, PhD, F. Gruenwald, MD, PhD, Osama Sabri, MD, PhD, Wolfgang Hirsch, MD, PhD, Dieter Korholz, MD, PhD

Blood (2005) 106 (11): 2672.

https://doi.org/10.1182/blood.V106.11.2672.2672

Published: 2005

Journal Articles

Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.

Blood (2005) 106 (11): 1851.

https://doi.org/10.1182/blood.V106.11.1851.1851

Published: 2005

Journal Articles

Characteristics of Immunoglobulin Deficiency in Patients with Untreated Multiple Myeloma Stage II and III.

Markus Hamel, MD, Wolfram Poenisch, MD, Dirk Hasenclever, PhD, Goetz Gelbrich, PhD, Markus Loeffler, MD, Haifa K. Al Ali, MD, Stefanie Lehmann, Dietger Niederwieser, MD, Karlheinz Merkle, MD

Blood (2004) 104 (11): 4861.

https://doi.org/10.1182/blood.V104.11.4861.4861

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Bernd Metzner, Dirk Hasenclever, Norbert Schmitz, Bertram Glass, Christian Rübe, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 626–633.

https://doi.org/10.1182/blood-2003-06-2094

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rübe, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Hartmut Eimermacher, Dirk Hasenclever, Norbert Schmitz, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 634–641.

https://doi.org/10.1182/blood-2003-06-2095

Published: 2004

Journal Articles

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia

Norbert Schmitz, Meral Beksac, Dirk Hasenclever, Andrea Bacigalupo, Tapani Ruutu, Arnon Nagler, Eliane Gluckman, Nigel Russell, Jane F. Apperley, Norbert C. Gorin, Jeff Szer, Ken Bradstock, Agnes Buzyn, Peter Clark, Keith Borkett, Alois Gratwohl

Blood (2002) 100 (3): 761–767.

https://doi.org/10.1182/blood-2001-12-0304

Published: 2002

NARROW

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Integrated Somatic Mutation and DNA Methylation Analysis Reveal Genomic and Epigenomic Co-Evolution In Follicular Lymphomas

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

Prognostic Impact of Early and Late 18 fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Prior to Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed or Refractory Hodgkin Lymphoma

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults

New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

Surgical Resection Alone in Children with Limited Stage Lymphocyte Predominant Hodgkin’s Lymphoma - The Experience of the EuroNet-PHL Group.

Treatment of Children & Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] - on Behalf of the EuroNet-PHL Group.

Response Adapted Therapy: Using FDG-PET after Chemotherapy in Order To Restrict Indication for Radiotherapy in Children and Adolescents with Early Stages of Hodgkin’s Lymphoma (HL).

Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.

Characteristics of Immunoglobulin Deficiency in Patients with Untreated Multiple Myeloma Stage II and III.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only